source
- InventisBio's Phase 3 Trial Shows Nomelcitinib Achieves Over 70% PASI-90 Response in Chinese Psoriasis PatientsInventisBio, a Shanghai‑based biotech, completed a phase 3 study of its TYK2 inhibitor nomelcitinib in 391 Chinese patients with moderate to severe psoriasis. Participants were randomized to receiv…
- Karyopharm files for Chapter 11 bankruptcy as it pursues merger with AyrmidKaryopharm Therapeutics has filed for Chapter 11 bankruptcy while seeking a merger with U.K. biotech Ayrmid. The court‑supervised process is intended to provide a financial lifeline for the company…